Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: JOHN W. who wrote (3831)	2/15/1998 9:55:00 PM
From: Henry Niman	Respond to of 6136

John, I just posted an article that cited a study that found that over 60% of patients on PIs (over a year) had altered metabolism. All reports that I have seen have indicated that the altered metabolism is associated with all four PIs currently approved. One paper cited a mechanism for the problem (cross reactivity between the protease region targeted by PIs and a receptor on liver cells). My posts came from wire services. None of them talk about specificity with a particular protease. The record thus far is fairly straightforward and none support your hypothesis. Good luck on finding something. I'm sure that if you do, you will share the data with readers of this board.